Key result
hs-CRP reliably predicts cardiovascular risk, and statins effectively lower CRP alongside lipids.
Why the study?
Vascular inflammation contributes to plaque vulnerability and is strongly associated with future cardiovascular events, yet whether lowering inflammatory markers such as C-reactive protein directly reduces cardiovascular risk remains unknown.
Answers are grounded in this paper and cite their sources.
This review highlights the role of vascular inflammation in plaque vulnerability, identifies high-sensitivity C-reactive protein as the most accessible systemic marker for cardiovascular risk, and notes that while statins reduce CRP levels, it remains unknown if CRP reduction alone decreases cardiovascular risk.
Inflammation occurs in the vasculature as a response to injury, lipid peroxidation, and perhaps infection. Various risk factors, including hypertension, diabetes, and smoking, are amplified by the harmful effects of oxidized low-density-lipoprotein cholesterol, initiating a chronic inflammatory reaction, the result of which is a vulnerable plaque, prone to rupture and thrombosis. Epidemiological and clinical studies have shown strong and consistent relationships between markers of inflammation and risk of future cardiovascular events. Inflammation can potentially be detected locally by imaging techniques as well as emerging techniques, such as identification of temperature or pH heterogeneity. It can be detected systemically by measurement of inflammatory markers. Of these, the most reliable and accessible for clinical use is currently high-sensitivity C-reactive protein. A combination of methods may provide the best identification of persons at risk for cardiovascular events who would benefit from treatment. In randomized, controlled trials, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in the form of statins, have been shown to provide effective therapy for lowering CRP, in conjunction with their lipid-lowering effects. Although the magnitude of risk reduction associated with statin use appears to be largest for those with the highest serum levels of CRP, whether CRP reduction per se lowers cardiovascular risk is unknown.
No takes yet. Share an insight, caveat, or question.
Willerson et al. (2004) conducted a review in Cardiovascular disease risk / vascular inflammation. Statins (HMG-CoA reductase inhibitors) / hs-CRP measurement was evaluated on Future cardiovascular events and C-reactive protein (CRP) reduction. High-sensitivity C-reactive protein is the most reliable clinical inflammatory marker for cardiovascular risk, and statins effectively lower CRP alongside lipids.
Synapse has enriched 10 related papers. Consider them for comparative context: